ATHE vs. LIAN, ICCC, VYNE, NKGN, PLUR, RVPH, SRZN, ZIVO, ACST, and OCX
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include LianBio (LIAN), ImmuCell (ICCC), VYNE Therapeutics (VYNE), NKGen Biotech (NKGN), Pluri (PLUR), Reviva Pharmaceuticals (RVPH), Surrozen (SRZN), ZIVO Bioscience (ZIVO), Acasti Pharma (ACST), and OncoCyte (OCX). These companies are all part of the "pharmaceutical products" industry.
Alterity Therapeutics (NASDAQ:ATHE) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability.
Alterity Therapeutics has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.
In the previous week, Alterity Therapeutics had 3 more articles in the media than LianBio. MarketBeat recorded 3 mentions for Alterity Therapeutics and 0 mentions for LianBio. Alterity Therapeutics' average media sentiment score of 0.52 beat LianBio's score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the media.
2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Alterity Therapeutics' return on equity of 0.00% beat LianBio's return on equity.
Alterity Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 148.45%. LianBio has a consensus price target of $5.33, suggesting a potential upside of 1,641.55%. Given LianBio's higher possible upside, analysts clearly believe LianBio is more favorable than Alterity Therapeutics.
LianBio received 1 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. However, 60.00% of users gave Alterity Therapeutics an outperform vote while only 36.36% of users gave LianBio an outperform vote.
Summary
Alterity Therapeutics beats LianBio on 9 of the 12 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
Free ATHE Stock Alerts